164 results on '"Chamuleau, Martine E. D."'
Search Results
2. Epcoritamab monotherapy in patients with relapsed or refractory follicular lymphoma (EPCORE NHL-1): a phase 2 cohort of a single-arm, multicentre study
3. Genomic profiling of post-transplant lymphoproliferative disorders using cell-free DNA
4. A population-based study of transformed marginal zone lymphoma: identifying outcome-related characteristics
5. A non-randomized risk-adjusted comparison of lenalidomide + R-CHOP versus R-CHOP for MYC-rearranged DLBCL patients
6. Distinct peripheral T-cell and NK-cell profiles in HGBL-MYC/BCL2 vs patients with DLBCL NOS
7. R-CODOX-M/R-IVAC versus DA-EPOCH-R in patients with newly diagnosed Burkitt lymphoma (HOVON/SAKK): final results of a multicentre, phase 3, open-label, randomised trial
8. Baseline radiomics features and MYC rearrangement status predict progression in aggressive B-cell lymphoma
9. R-CEOP as first-line treatment for anthracycline-ineligible patients with diffuse large B-cell lymphoma
10. Dose escalation of subcutaneous epcoritamab in patients with relapsed or refractory B-cell non-Hodgkin lymphoma: an open-label, phase 1/2 study
11. Time trends in primary therapy and relative survival of diffuse large B-cell lymphoma by stage: a nationwide, population-based study in the Netherlands, 1989–2018
12. Survival disparities between children and adolescents and young adults for the major subtypes of non-Hodgkin lymphoma in the Netherlands: a large population-based study
13. The Dutch CAR-T Tumorboard Experience: Population-Based Real-World Data on Patients with Relapsed or Refractory Large B-Cell Lymphoma Referred for CD19-Directed CAR T-Cell Therapy in The Netherlands
14. No sex differential in relative survival among older patients with DLBCL treated with R-CHOP21: a population-based study
15. P1159: INFERIOR OUTCOME OF FRAIL AND UNFIT PATIENTS WITH DIFFUSE LARGE B-CELL LYMPHOMA TREATED WITH ATTENUATED R-CHOP
16. Epcoritamab induces potent anti-tumor activity against malignant B-cells from patients with DLBCL, FL and MCL, irrespective of prior CD20 monoclonal antibody treatment
17. DuoHexaBody-CD37®, a novel biparatopic CD37 antibody with enhanced Fc-mediated hexamerization as a potential therapy for B-cell malignancies
18. An artificial intelligence method using FDG PET to predict treatment outcome in diffuse large B cell lymphoma patients.
19. The path towards consensus genome classification of diffuse large B-cell lymphoma for use in clinical practice
20. First-Line Treatment of Waldenström’s Macroglobulinaemia: Considerations Based on the Dutch National Guideline
21. Chemotherapy resistant Burkitt lymphoma: Possible novel therapies including CAR‐T cell infusion.
22. Final results of a phase 1b study of the safety and efficacy of the PI3Kδ inhibitor acalisib (GS-9820) in relapsed/refractory lymphoid malignancies
23. Biological and Clinical Implications of Gene-Expression Profiling in Diffuse Large B-Cell Lymphoma: A Proposal for a Targeted BLYM-777 Consortium Panel as Part of a Multilayered Analytical Approach
24. Combining Ixazomib With Subcutaneous Rituximab and Dexamethasone in Relapsed or Refractory Waldenström's Macroglobulinemia: Final Analysis of the Phase I/II HOVON124/ECWM-R2 Study
25. Dose-adjusted EPOCH-R plus venetoclax: a toxic bend in the road to improving R-CHOP?
26. Subcutaneous (SC) epcoritamab induces complete responses across R/R B-cell NHL subtypes: Updated dose-escalation data
27. Potent preclinical activity of HexaBody-DR5/DR5 in relapsed and/or refractory multiple myeloma
28. Treatment of patients with MYC rearrangement positive large B-cell lymphoma with R-CHOP plus phaselenalidomide: II HOVON trial results of a multicenter
29. Alternative Ii-independent antigen-processing pathway in leukemic blasts involves TAP-dependent peptide loading of HLA class II complexes
30. Potent Preclinical Efficacy of DuoHexaBody-CD37 in B-Cell Malignancies
31. Double Hit Lymphoma Diagnosis and Treatment in Europe—A Cross-Sectional Survey of Clinical Practice by the EHA Lymphoma Working Party (EHA LyG)
32. Impact of MYC on Anti-Tumor Immune Responses in Aggressive B Cell Non-Hodgkin Lymphomas: Consequences for Cancer Immunotherapy
33. Fc-Engineered Antibodies with Enhanced Fc-Effector Function for the Treatment of B-Cell Malignancies
34. Detection of aberrant transcription of major histocompatibility complex class II antigen presentation genes in chronic lymphocytic leukaemia identifies HLA-DOA mRNA as a prognostic factor for survival
35. Feasibility and efficacy of addition of individualized dose lenalidomide to chlorambucil and rituximab as first-line treatment in elderly and FCR-unfit patients with advanced chronic lymphocytic leukemia
36. Ixazomib, Rituximab and Dexamethasone (IRD) in Patients with Relapsed or Progressive Waldenstrom's Macroblobulinemia: Results of the Prospective Phase I/II HOVON 124/Ecwm-R2 Trial
37. Venetoclax plus R- or G-CHOP in non-Hodgkin lymphoma: results from the CAVALLI phase 1b trial
38. CD20 and CD37 antibodies synergize to activate complement by Fc-mediated clustering
39. A population-based study on different regimens of R-CHOP in patients with newly diagnosed DLBCL in The Netherlands.
40. Distinct peripheral T-cell and NK-cell profiles in HGBL-MYC/BCL2vs patients with DLBCL NOS
41. DuoHexaBody-CD37®, a novel biparatopic CD37 antibody with enhanced Fc-mediated hexamerization as a potential therapy for B-cell malignancies.
42. Treatment and relative survival in very elderly patients with DLBCL in The Netherlands: a population-based study, 1989 to 2015
43. ZAP70 in B-CLL cells related to the expression in NK cells is a surrogate marker for mutational status
44. Intracerebral lymphoproliferative disorder in an MS patient treated with fingolimod.
45. Aberrant immunophenotype of blasts in myelodysplastic syndromes is a clinically relevant biomarker in predicting response to growth factor treatment
46. Detection of aberrant transcription of major histocompatibility complex class II antigen presentation genes in chronic lymphocytic leukaemia identifiesHLA-DOAmRNA as a prognostic factor for survival
47. 18F-FDG or 3'-Deoxy-3'-18F-Fluorothymidine to Detect Transformation of Follicular Lymphoma.
48. Class II-Associated Invariant Chain Peptide Expression on Myeloid Leukemic Blasts Predicts Poor Clinical Outcome
49. ZAP70 in B-CLL cells related to the expression in NK cells is a surrogate marker for mutational status.
50. Tumor immune escape in acute myeloid leukemia: Class II-associated invariant chain peptide expression as result of deficient antigen presentation.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.